Evidence for using first-line coagulation factor concentrates for trauma- induced coagulopathy

In ICU
Tue, 16 Oct 2018

ICU Management & Practice, Volume 18 - Issue 3, 2018

Fibrinogen limits coagulopathy and massive bleeding, has less transfusion requirements and thereby decreases the risk of multi-organ failure in trauma patients.

What stops the bleeding?

Haemostatic therapy aims to stop the bleeding, but is it a concentration of coagulation factors, mainly assessed by international normalised ratio (INR) readings that works, or is it fibrinogen/fibrin, which are the precondition for stable clot formation? We conducted a study in patients with polytrauma and those with isolated brain injury (Tauber et al. 2011) to find out what the most predominant pathology was (Figure 1). The red bars refer to polytrauma patients. There is significant increase in the frequency of low fibrinogen, low fibrinpolymerization and consequently low clot firmness, in 20-30%, while a significant and prolonged INR of about 1.5 was found in only about 14%. Clot firmness and fibrin polymerization were independently associated with mortality and also with blood loss as measured by early transfusion requirements. In addition patients had tremendously increased molecular markers of thrombin generation, regardless of the INR readings. It’s not the main interest to increase it more by substituting plasma, because very huge thrombin levels do not benefit trauma patients. It may cause endothelial injury and also activate other receptors and inflammation and so on.

Further results confirm these findings, e.g. in a study that included more than 4,000 patients, with injury severity scores (ISS) considerably lower than in our patient population, fibrinogen deficiency occurred frequently and fibrinogen levels < 1.5g/L were associated with increased mortality (McQuilten et al. 2017). Hagemo et al.’s study investigating 1,133 patients in a multicentre trial, found that increased mortality was associated with fibrinogen levels < 2.29 g/L, which is barely below normal (Hagemo et al. 2014). The INR was not independently associated with mortality.

Coagulation factor substitutes

Plasma

Plasma refers to 6-8% protein solution and 92-94% water. It was introduced in clinical practice mainly for volume substitution but later to treat coagulation disorders. It contains all procoagulants and also anticoagulants. It’s easy to use, is considered safe regarding thrombosis, and relatively low-cost. However, plasma transfusion is time-consuming and requires planning.

The concentration of coagulation factors and especially fibrinogen are rather low in plasma and vary depending on the individual donor and the type of processing. Plasma efficacy can be questioned and partial requirements correction is not possible. It may also induce transfusion-associated circulatory overload (TACO), transfusion-associated lung injury (TRALI), transfusion-associated immunomodulation (TRIM), multi-organ failure (MOF), immunosuppression, lung injury.

Fibrinogen concentrate

There are several concentrates on the market:

1. Fibrinogen concentrate

2. FXIII concentrate

3. PCC (FII, VII, IX, X)

4. vWF concentrate

5. rVIIa, PCCa

6. FVIII, IX, X, XI concentrate

No factor V concentrate is available.

Concentrates are immediately ready to use, contain defined and high concentration of the factor, no volume expansion is needed, so there will be an effective rise in concentration, making targeted therapy possible. There will be no TACO, TRALI or TRIM and the concentrates are virus-inactivated.

The main problem is cost; they are more expensive than plasma. Some may be concerned about the risk of thromboembolism, and this may occur if thrombin formation is increased by use of PCC and activated PCC and rFVIIa. It is not a problem with fibrinogen, which is also called antithrombin I, as fibrinogen and fibrin are able to capture free-flowing thrombin, and thrombin is the one that initiates thrombosis. Authors of reviews and meta-analyses also criticise the fact that currently there are only a few high-quality studies in trauma patients showing a benefit with coagulation factor concentrates.

The European guideline (Rossaint et al. 2016) recommends the use of standard coagulation tests and/or viscoelastic tests (level of evidence 1C). Viscoelastic testing gives a timely and more comprehensive picture. The guideline recommends use of plasma together with RBC at least 1:2 or use of fibrinogen concentrate with RBC and PCC and factor XIII in selected cases.

Evidence for fibrinogen concentrate

The most frequently cited studies using coagulation factor concentrates in trauma patients are summarised in Table 1. All show promising results: lower mortality than predicted, lower transfusion requirements, and lower multi-organ failure. Fibrinogen was maintained within a normal range even if much fibrinogen had been administered. There were fewer transfusions of red blood cells (RBCs) and platelets. In the study by Wafaisade and colleagues (2013), early mortality was also reduced. These patients received fibrinogen and also had massive transfusions of plasma.

Meta-analyses on plasma efficacy in bleeding patients have concluded that there is no clear benefit for blood loss, transfusion and mortality (Stanworth et al. 2004; Casbard et al. 2004; Yang et al. 2012; Kozek-Langenecker et al. 2011; Desborough et al. 2015). However, there are several reports in trauma patients showing improved survival with early aggressive transfusion without any blood measurements. Administration of 1:1 ratios is recommended, but there are studies that found that mortality did not change and coagulopathy was not corrected (Table 2).

Before massive transfusion of plasma, reported mortality in many centres was about 50 percent. Now the rate is between 21% and 35% (Table 3). This mortality is considerably higher than studies using a targeted correction of coagulopathy and using coagulation factor concentrates, especially fibrinogen concentrate.

RETIC trial comparing plasma and coagulation factor concentrates

Our study group conducted the first randomised controlled trial comparing the effect of a plasma-based strategy to the use of coagulation factor concentrate in severe trauma (Innerhofer 2017). The study was terminated early following interim analysis after inclusion of 100 patients, because predefined stopping was met, showing disadvantages with use of plasma. Correction of coagulopathy was feasible in 96% of patients in the CFC group; only 2 patients had treatment failure and also received plasma (Table 4).

In the plasma group more than 50% of patients had no stop of bleeding and no correction of coagulation. These patients received additionally fibrinogen concentrate, some also PCC and factor XIII. Transfusion requirements were increased and patients received more frequently platelet concentrates. Importantly, the rate of massive transfusion at comparable ISS was increased tremendously.

Our primary endpoint was difference in MOF. However, to answer this question, we would have needed to include at least 200 patients. Therefore the difference of 16% between groups with a higher rate of MOF in the plasma group was not significant. However, ISS and brain injury are confounders, which should be considered when analysing the likelihood of MOF. These confounders were used for stratification and considered in regression analysis. Results showed a significant increased risk of MOF with plasma (OR 3·13 [1·19–8·88], p=0·025) even in this limited population of 94 patients.

What stops the bleeding–the concentration or the clot?

In the RETIC study the blue boxes refer to the CFC group that mainly received fibrinogen concentrate. The yellow boxes refer to the plasma group (Figure 2). Prothrombin is indexed as a percentage of normal, and at baseline they are comparable. After administration of plasma this improved, but decreased further in the CFC group. The patients in the plasma group received more RBC and platelets concentrates and, despite this, had a dramatic drop in platelet count. Also the haemoglobin levels were lower than in the CFC group that received fewer RBCS and platelets. Therefore improved INR or prothrombin time does not limit blood loss. What about fibrinogen and clot firmness? Fibrinogen increased to its normal levels immediately with the factor-based concept, but changed little and marginally and remained below normal in the plasma group. Consequently clot strength improved rapidly with CFC but remained unchanged or decreased in the plasma group.

Conclusion/ Key points

Early and effective fibrinogen supplementation is really important to limit blood loss and minimise risk of MOF
Fibrinogen improves clot strength and also exhibits a platelet-saving effect.This is very important because platelets are one of the transfusion components that are sometimes dangerous and have many side effects
Fibrinogen limits coagulopathy and massive bleeding and has less transfusion requirements especially massive transfusion and thereby it also decreases the risk of MOF
An effective rise of fibrinogen concentration is not feasible with plasma
The lower, better INR after plasma does not reduce the bleeding, therefore we should not focus on the INR
Fibrinogen is of interest, should be monitored and should be supplemented early

Abbreviations

ISS injury severity score

MOF multi-organ failure

TACO transfusion-associated circulatory overload

TRALI transfusion-associated lung injury

TRIM transfusion-associated immunomodulation

«« Clinical significance of viral detection in critically ill patients

Sink traps source of antibiotic-resistant bacteria in ICU »»

References:

Casbard AC, Williamson LM, Murphy MF et al. (2004) The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia, 59(6): 550-8.

Chambers LA, Chow SJ, Shaffer LE (2011) Frequency and characteristics of coagulopathy in trauma patients treated with a low- or high-plasma-content massive transfusion protocol. Am J Clin Pathol, 136(3): 364-70.

Davenport R, Curry N, Manson J et al. (2011) Hemostatic effects of fresh frozen plasma may be maximal at red cell ratios of 1:2. J Trauma, 70(1): 90-5.

Desborough M, Sandu R, Brunskill SJ et al. (2015) Fresh frozen plasma for cardiovascular surgery. Cochrane Database Syst Rev, (7): CD007614.

Dirks J, Jørgensen H, Jensen CH et al. (2010) Blood product ratio in acute traumatic coagulopathy--effect on mortality in a Scandinavian level 1 trauma centre. Scand J Trauma Resusc Emerg Med, 18: 65.

Duchesne JC, Islam TM, Stuke L et al. (2009) J Trauma, 67(1): 33-7. Hemostatic resuscitation during surgery improves survival in patients with traumatic-induced coagulopathy.

Edens JW, Chung KK, Pamplin JC et al. (2010) Predictors of early acute lung injury at a combat support hospital: a prospective observational study. J Trauma, 69 Suppl 1: S81-6.

Gonzalez EA, Moore FA, Holcomb JB et al. (2007) Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma, 62(1): 112-9.

Gonzalez E, Moore EE, Moore HB et al. (2016) 13. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg, 263(6): 1051-9.

Hagemo JS, Stanworth S, Juffermans NP et al. (2014) Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study. Crit Care, 18(2): R52.

Hirshberg A, Dugas M, Banez EI et al. (2003) Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma, 54(3): 454-63.

Holcomb JB, del Junco DJ, Fox EE et al.; PROMMTT Study Group (2013) The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg, 148(2): 127-36.

Holcomb JB, Tilley BC, Baraniuk S et al. (2015) Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA, 313(5): 471-82.

Innerhofer P, Westermann I, Tauber H et al. (2013) The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury, 44(2): 209-16.

Innerhofer P, Fries D, Mittermayr M et al. (2017) Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol, 4(6): e258-e271.

Johnson JL, Moore EE, Kashuk JL et al. (2010) Effect of blood products transfusion on the development of postinjury multiple organ failure. Arch Surg, 145(10): 973-7.

Kashuk JL, Moore EE, Johnson JL et al. (2008) Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma, 65(2): 261-70.

Khan S, Brohi K, Chana M et al; International Trauma Research Network (INTRN) (2014) Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage. J Trauma Acute Care Surg, 76(3): 561-7.

Kozek-Langenecker S, Sørensen B, Hess JR et al. (2011) Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care, 15(5): R239.

Maegele M, Lefering R, Paffrath T et al.; Working Group on Polytrauma of the German Society of Trauma Surgery (DGU) (2008) Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: a retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie. Vox Sang, 95(2): 112-9.

Magnotti LJ, Zarzaur BL, Fischer PE et al. (2011) Improved survival after hemostatic resuscitation: does the emperor have no clothes? J Trauma, 70(1): 97-102.

McQuilten ZK, Wood EM, Bailey M et al. (2017) Fibrinogen is an independent predictor of mortality in major trauma patients: A five-year statewide cohort study. Injury, 48(5): 1074-81.

Mitra B, Mori A, Cameron PA et al. (2010) Fresh frozen plasma (FFP) use during massive blood transfusion in trauma resuscitation. Injury, 41(1): 35-9.

Nascimento B, Callum J, Tien H, et al. (2013) Effect of a fixed-ratio (1:1:1) transfusion protocol versus laboratory-results-guided transfusion in patients with severe trauma: a randomized feasibility trial. CMAJ, 185(12): E583-9.

Nienaber U, Innerhofer P, Westermann I et al. (2011) The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury, 42(7): 697-701.

Peiniger S, Nienaber U, Lefering R et al.; Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie (2011) Balanced massive transfusion ratios in multiple injury patients with traumatic brain injury. Crit Care, 15(1): R68.

Rangarajan K, Subramanian A, Pandey RM (2011) Determinants of mortality in trauma patients following massive blood transfusion. J Emerg Trauma Shock, 4(1): 58-63.

Rossaint R, Bouillon B, Cerny V et al. (2016) The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care, 20: 100.

Rourke C, Curry N, Khan S et al. (2012) Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost, 10(7): 1342-51.

Scalea TM, Bochicchio KM, Lumpkins K et al. (2008) Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg, 248(4): 578-84.

Schlimp CJ, Voelckel W, Inaba K et al. (2013) Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/- fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study. Scand J Trauma Resusc Emerg Med, 21: 74.

Schöchl H, Nienaber U, Hofer G et al. (2010) Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care, 14(2): R55.

Schöchl H, Nienaber U, Maegele M et al. (2011) Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care, 15(2): R83.

Snyder CW, Weinberg JA, McGwin G Jr et al. (2009) The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma, 66(2): 358-62.

Stanworth SJ, Brunskill SJ, Hyde CJ et al. (2004) Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol, 126(1): 139-52.

Tauber H, Innerhofer P, Breitkopf R et al. (2011) Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth, 107(3): 378-87.

Teixeira PG, Inaba K, Shulman I et al. (2009) Impact of plasma transfusion in massively transfused trauma patients. J Trauma, 66(3): 693-7.

Wafaisade A, Lefering R, Maegele M et al.; Trauma Registry of DGU (2013)

Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge. J Trauma Acute Care Surg, 74(2):387-93.

Yang L, Stanworth S, Hopewell S et al. (2012) Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion, 52(8):1673-86.